Channels: Glaucoma | Posted 1/25/2017
Jason Bacharach, MD, discussed his excitement regarding results from studies of netarsudil (Aerie), a potential first in a new class of glaucoma medications in 2 decades. The agent was found to be noninferior to timolol in the Rocket 1 and Rocket 2 studies. He also spoke about a fixed-dose agent from the company, PG324, a combination of netarsudil and latanoprost. This would potentially be the first fixed-dose combination drug that contains a prostaglandin available in the United States.